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Alpha-lipoic acid prevents atrial electrical and structural remodeling via inhibition of
NADPH oxidase in a rabbit rapid atrial pacing model
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Background/aim: Alpha-lipoic acid (ALA) is a natural compound, one of the natural antioxidants with high activity. In the NADPH
oxidase family, NADPH oxidase 4 (NOX4) is an important subunit participating in the production of ROS. NADPH oxidase 2 (NOX2)
can form active NADPH oxidase complexes when binding to several other subunits in the cytoplasm, and NOX2 is its major functional
subunit. Rapid atrial pacing (RAP) model was constructed to study the effects of ALA on electrical and structural remodeling in rabbits.
Materials and methods: Thirty rabbits were divided into SHAM group, RAP group and ALA+RAP group. Their right atriums were
paced at a speed of 600 beats/min for 12 h in the RAP and ALA+RAP groups, and the atrial effective refractory period (AERP) and AERP
frequency adaptability were determined during the pace. In ALA+RAP group, ALA (30 mg/kg) was administered intraperitoneally
daily to the rabbits for 3 days before RAP. Atrial tissue was collected from each group to detect malondialdehyde (MDA), superoxide
dismutase (SOD) and reactive oxygen species (ROS) to observe the effect of oxidative stress. The pathological structure of the atrial tissue
was observed through hematoxylin-eosin (HE) staining. Ultrastructural changes in the atrial myocytes were observed by transmission
electron microscopy (TEM), and the expression levels of Nox2 and Nox4 were detected by immunohistochemistry, western blot and
ELISA.
Results: AERP gradually shortened, while ALA injection could remarkably delay this process. HE staining showed that the most of the
nuclei appeared normal, the myocardial fibers did not show ruptures, and their arrangement was slightly ordered, and myofilament
dissolution and mitochondrial swelling and deformation were rarely observed by TEM in the ALA+RAP group. Compared with the
RAP group, the contents of MDA and ROS were reduced, SOD activity was enhanced, and the expression of NOX2 and NOX4 was
decreased in the ALA+RAP group.
Conclusion: ALA can inhibit atrial electrical remodeling and structural remodeling, and its mechanism may be related to inhibiting the
activity of NADPH oxidase.
Key words: NADPH oxidase, rapid atrial pacing, reactive oxygen species, oxidative stress, alpha-lipoic acid

1. Introduction
Atrial fibrillation (AF) is one of the most common
arrhythmias encountered in the clinic [1]. Atrial
fibrillation-induced symptoms and complications can
severely affect the quality of life and cause mortality [2–
4]. Long-term maintenance of the sinus rhythm of AF
remains a considerable challenge due to its complicated
pathogenesis. The available methods for controlling the
AF rhythm include antiarrhythmic drugs and catheter
ablation, both of which have obvious limitations [5, 6].
Upstream treatment of AF is a novel method introduced in
recent years and it aims to achieve primary and secondary
prevention of AF [7]. It was first established in 2010 by

the European Society of Cardiology to be a new method
and strategy to prevent AF [8]. However, the precise
mechanism of the genesis and development of AF remains
incompletely known. Therefore, additional research on the
genesis and maintenance of AF is of crucial importance.
Many studies have indicated that atrial remodeling
is the central link for the genesis and maintenance of
AF, which mainly includes atrial electrical remodeling,
structural remodeling and contractile remodeling [9–11].
As research continues in recent years, growing evidence
has indicated that oxidative stress plays an important
role in atrial remodeling [12–14]. In oxidative stress,
superoxide dismutase (SOD) is the most important enzyme
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in the first-line cellular defense [15], and it is extensively
distributed in all tissue and cells. Malondialdehyde (MDA)
is the end byproduct of lipid peroxidation in oxidative
stress [16], which is frequently treated as a detection index
of lipid peroxidation degree. In addition, a large amount of
reactive oxygen species (ROS) will be produced in the case
of oxidative stress, which plays a vital role in AF [17,18].
Consequently, effective regulation of ROS levels in vivo has
become an important intervention target in the upstream
treatment of AF. ROS has numerous sources in vivo, but
many studies have suggested that nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase is its primary
source [19–21]. In the NADPH oxidase family, NOX4 is an
important subunit participating in the production of ROS
[22, 23]. Gp91phox (NOX2) and p22phox subunits are
located on the plasma membrane, which can form active
NADPH oxidase complexes when binding to several other
subunits (including NOX4) in the cytoplasm, and NOX2
is its major functional subunit. Plenty of evidence from
clinical and experimental research has indicated that ROS
plays a core role in numerous cardiovascular diseases
(CVD’s, including AF). However, the clinical effects of
antioxidant stress treatment are not satisfactory. This may
be because a general ROS scavenger can only neutralize
one or several forms of ROS, while other ROS forms still
exert a proarrhythmic effect [24,25]. Therefore, a more
comprehensive ROS scavenger or a targeted therapy
specific to each ROS source is required.
Alpha-lipoic acid (ALA) is a natural compound,
one of the natural antioxidants with high activity [26].
Compared with other natural antioxidants such as vitamin
C and carotene, ALA is water and lipid soluble, and it
can exist in the cytoplasm and cell membrane. Moreover,
it has been applied in diabetes [27], CVD [28] and liverkidney disease [29]. ALA can eliminate ROS and reduce
the production of ROS by targeting NADPH oxidase
[30–32]. Therefore, compared with general antioxidants,
ALA cannot only more comprehensively eliminate active
substances in vivo but also target NADPH oxidase. So far,
research on the role of ALA in CVD has been reported,
but only a limited number of studies have reported on its
effects on arrhythmia. This study constructed a rapid atrial
pacing (RAP) rabbit model to evaluate the effect of ALA
on atrial remodeling in AF and its possible mechanism.
Hopefully, this research can provide a new possibility for
the clinical treatment of AF.
2. Materials and methods
2.1. Animals
In this study, 30 healthy New Zealand white rabbits
weighing 2.9 ± 0.2 kg (2.7–3.1 kg) were selected regardless
of sex. All rabbits were randomly assigned to the SHAM
group (n = 10), the RAP group (n = 10), or the ALA + RAP

group (n = 10). Rabbits were housed under conventional
conditions and exposed to light-dark cycle of 12 h with free
access to water and food. Continuous care was provided
throughout the study to ensure prompt intervention when
needed. All rabbits were obtained from Xuzhou Medical
University Animal Center. This study was approved by the
Animal Ethics Committee of Xuzhou Medical University
Animal Center.
2.2. ALA solution preparation
ALA was purchased from Yuanye Biotechnology (Shanghai,
China). ALA (80 mg/mL) was dissolved in 10% ethanol
and sterilized by filtering. ALA solutions were prepared
immediately before use. In the ALA+RAP group, dissolved
ALA (0.375 mL/kg) was administered intraperitoneally
daily (i.p.) to the rabbits for 3 days before RAP [31]. In
the remaining groups, equal volume of normal saline was
injected intraperitoneally.
2.3. Construction of the rapid atrial pacing (RAP) model
First, 1% pentobarbital sodium solvent was injected
slowly through the ear vein at 2 mL/kg. After successful
anesthesia induction, the anesthesia was maintained
through an indwelling needle in the ear vein and a constant
speed micropump. An incision was made in the middle
of the neck, the trachea was isolated, tracheal intubation
was conducted, and an animal ventilator was connected
to assist in ventilation. The right internal jugular vein
was isolated, and distal shaping of the 10-pole coronary
sinus electrode was conducted, which was sent to the right
atrium through the 6F sheathing canal, and the chest lead
V1 was connected to the distal end of the coronary sinus
buttock line.
The BL-420s biological function experimental system
(TECHMAN, Chengdu, China) was connected, and
continuous stimuli were released at a frequency 10%–20%
higher than the sinus rhythm. Microadjustment of the
coronary sinus electrode direction was performed so that
the stimulating electrode adhered to the right atrium.
Then, 1:1 atrial and ventricular conduction observed
simultaneously in the intracavity lead and the body
surface lead electrocardiograms revealed complete atrial
pacing. The position of the coronary sinus electrode was
maintained, and 12 h continuous stimuli were carried out
by pacing at a rate of 600 times/min at a pressure twice
that of the pacing threshold. After pacing, the rabbits
were euthanized by intravenous injection of 100 mg/kg
pentobarbital sodium.
2.4. AERP determination
The 2-fold diastolic pacing threshold was treated as the
output voltage, and the pulse width was set at 0.5 ms to
measure AERP under the basic condition. Programmed
premature extrastimulation (S1S2) was adopted at a
stimulation frequency of 8:1. Decreasing scanning was
carried out at S1S2 interphase at a step length of 10 ms
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and a scanning interval of 30 s. The refractory period was
defined as the longest S1S2 interphase that S2 did not
induce atrial activation in the time of S1S2 stimulation.
AERP was measured 3 times, and the mean was treated as
the baseline AERP value. AERP200 and AERP150 at the
S1S1 of 200 ms and 150 ms were measured, respectively.
The frequency adaptability is expressed as AERP200 −
AERPl50. Rapid atrial pacing was performed at the rate
of 600 bpm in RAP group and ALA+RAP group. The
AERP was measured repeatedly at 0h, 4h, 8h and 12h after
pacing. In SHAM group, AERP was only measured at the
same time, but not rapid pacing.
2.5. Tissue processing
The hearts were excised and washed immediately
with buffered saline (pH 7.4) to remove any red blood
cells and clots. The tissues were then weighed and
homogenized in normal saline (0.9%) for 2 min. The
heart tissue was first divided into three parts, one of
which was homogenized to complete the determination
of WB, ELISA and oxidative stress indexes. All
homogenate samples were centrifuged for 20 min at
3000 rpm at 4 °C in a refrigerated centrifuge to remove
debris. The other part of the tissue was fixed and sliced
to complete H&E staining and immunohistochemistry.
The last part was fixed and sent to Neuroelectrometer
Experimental Center of Xuzhou Medical University
for processing to complete transmission electron
microscopy observation.
2.6. Detection of NOX4 and oxidative stress-related
parameters
Atrial tissue was collected from each group to detect
malondialdehyde (MDA), superoxide dismutase (SOD)
and reactive oxygen species (ROS) to observe the effect of
oxidative stress. After the tissue homogenate was completed,
the levels of MDA, SOD and ROS were detected by using
the respective assay kits according to the instructions.
ROS detection kits were purchased from Beyotime
Biotechnology (Shanghai, China). MDA detection kits
and SOD activity assay kits were obtained from Nanjing
Jiancheng Bioengineering Institute (Nanjing, China). The
levels of the NOX4 protein were determined by ELISA.
The ELISA kits for the protein Nox4 were purchased from
Westang Biotechnology (Shanghai, China).
2.7. Histopathological analysis
Samples of heart tissues were washed immediately with
saline (0.9%) and fixed in 10% phosphate buffered formalin
solution for 24 h. The tissues were then dehydrated in
ascending grades of ethyl alcohol, cleared with xylene,
and embedded in paraffin. Paraffin blocks were cut by a
microtone to prepare 5 μm thick sections. Sections were
stained with hematoxylin-eosin (H&E) to stain the nucleus
and cytoplasm.
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2.8. Ultrastructural changes
After precooling the relevant instruments at 4 °C, the
samples of heart tissues were washed with saline (0.9%)
then cut into 1 × 1 × 1 mm3 pieces and placed immediately
in 4% glutaraldehyde at 4 °C for 4 h. Afterward, the
samples were sent to the Neuroelectrometer Experimental
Center of Xuzhou Medical University, sliced and stained,
and observed by transmission electron microscopy
(HITACHI, Japan).
2.9. Immunohistochemistry
For the detection of NOX-2, paraffin sections were
deparaffinized, rehydrated and washed in 0.05 M Trisbuffered saline (TBS) pH 7.6. Immunostaining was
performed using a rabbit polyclonal antibody (antiNOX2) at a dilution of 1:250 for 1 h at room temperature.
Negative controls were performed by omission of the
primary antibody. Then, the sections were incubated
with NovoLink Polymer Detection System (product No.
RE 7280-K; Leica Biosystems, Newcastle, UK) for 30 min
to detect any tissue-bound primary antibody. Sections
were further incubated with the substrate/chromogen,
3,3-diaminobenzidine (DAB), prepared from Novocastra
DAB chromogen (50 μl) and 1 mL of NovoLink Substrate
Buffer (Polymer). Washing with TBS (0.05 M, pH 7.6) twice
for 5 min was performed following each step of incubation.
Immunostained sections were then counterstained with
Mayer’s hematoxylin. Finally, sections were dehydrated
rapidly in ascending grades of ethanol, cleared in xylene,
and mounted in DPX mounting medium. The stained
sections were evaluated and photographed using an
Olympus BX51 bright field microscope equipped with an
Olympus DP72 camera (Olympus Corporation, Japan).
Anti-NOX2 was purchased from Bioss Biotechnology
(Beijing, China).
2.10. Western blot
The whole-cell lysates of the cortical samples (N = 3 for
each group) were obtained using tissue protein extraction
kits supplemented with protease inhibitors (Roche, IN,
USA). The total protein concentration was determined
using BCA kits. An equal amount of protein was separated
by electrophoresis in 10% sodium dodecyl sulfate
polyacrylamide gels and then transferred to nitrocellulose
membranes. After washing with TBST, the blots were then
incubated with the respective secondary antibodies for 2
h and developed by chemiluminescence. Relative optical
densities of the blots were quantified by densitometry.
Rabbit polyclonal anti-NOX4 antibody was obtained from
Novus Biologicals (Littleton, USA).
2.11. Statistical analysis
SPSS 19.0 statistical software (SPSS, Chicago, Illinois, USA)
was adopted for statistical analysis. Measurement data
were expressed as mean ± standard deviation. Data among
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multiple groups at all time points were compared using
one-way analysis of variance. Differences in continuous
repeated measuring data were compared by the repeated
data analysis of variance. Further pairwise comparison
was carried out using a Dunnett t-test. Differences were
considered significant when p <0.05.

the RAP group, AERP200ms and AERP150ms in the
ALA+RAP group were increased at the corresponding
time points (p < 0.05) (Tables 1 and 2).
3.1.2. Effect of ALA on AERP frequency adaptability
AERP frequency adaptability in the SHAM group indicated
no distinct changes with an extension of pacing time
within 12 h, while they were notably changed in the RAP
group and the ALA+RAP group (p < 0.05). Compared
with the SHAM group, AERP frequency adaptability in
the RAP group was shortened at corresponding time
points (p < 0.05). Compared with the RAP group, AERP
frequency adaptability in the ALA+RAP group was
increased at corresponding time points (p < 0.05). AERP
frequency adaptability was shortened in the ALA+RAP
group at corresponding time points compared with the
SHAM group (p < 0.05) (Table 3).
3.2. Structural remodeling-related indicators
3.2.1. HE staining
The rabbits in the SHAM group (Figure 1a) showed
orderly myocardial fibers and normal nuclei. Atrial

3. Results
3.1. Electrical remodeling-related indicators
3.1.1. Effect of ALA on AERP
Differences in AERP200ms and AERP150ms among the
three groups under the basic condition (before pacing) were
not significant (p > 0.05). AERP200ms and AERP150ms
had no obvious variation trend with an extension in time
within 12 h in the SHAM group, while they were gradually
shortened with the extension of pacing time within 12
h in both the RAP group and the ALA+RAP group (p <
0.05). Compared with the SHAM group, AERP200ms
and AERP150ms were significantly shortened after rapid
pacing in the RAP group (p < 0.05). Compared with

Table 1. Effect of alpha-lipoic acid on AERP200ms (n=10, x̄ ±s, ms).
Group

0h

4h

8h

SHAM

115.60 ± 6.14

115.20 ± 6.09

115.95 ± 5.19

114.45 ± 7.58

RAP

116.84 ± 3.78

99.84 ± 5.05

87.92 ± 8.42

79.49 ± 7.83ab

ALA+RAP

116.92 ± 3.94

104.76 ± 9.96abc

100.77 ± 9.85abc

96.90 ± 4.43abc

ab

12h
ab

ms, millisecond; h, hour; a, p< 0.05 compared with the 0h of this group; b, p< 0.05 compared with the SHAM group; c,
p< 0.05 compared with the RAP group.
Table 2. Effect of alpha-lipoic acid on AERP150ms (n=10, x̄ ±s, ms).
Group

0h

4h

8h

SHAM

104.24 ± 6.63

103.62 ± 6.06

104.63 ± 5.26

103.97 ± 6.41

RAP

105.83 ± 4.05

89.43 ± 5.00

80.29 ± 8.36

76.07 ± 7.88ab

ALA+RAP

105.57 ± 3.87

94.28 ± 10.13abc

91.87 ± 10.00abc

89.39 ± 4.78abc

ab

12h
ab

ms, millisecond; h, hour; a, p< 0.05 compared with the 0h of this group; b, p< 0.05 compared with the SHAM group; c,
p< 0.05 compared with the RAP group.
Table 3. Effect of alpha-lipoic acid on AERP frequency adaptability (n=10, x̄ ±s, ms).
Group

0h

4h

8h

SHAM

11.36 ± 0.90

11.58 ± 0.25

11.32 ± 0.28

11.49 ± 0.35

RAP

11.01 ± 2.29

10.41 ± 0.19

7.62 ± 0.22

3.42 ± 0.36ab

ALA+RAP

11.35 ± 0.80

11.48 ± 0.30c

8.90 ± 0.25abc

7.26 ± 0.63abc

b

12h
ab

h, hour; a, p< 0.05 compared with the 0h of this group; b, p< 0.05 compared with the
SHAM group; c, p< 0.05 compared with the RAP group.
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muscle cell hypertrophy could be seen in the RAP
group (Figure 1b) along with irregularly sized nuclei,
many nuclei showed pyknosis, there were disorderly
myocardial fibers, and myocardial fibers rupturing
and dissolving in some regions. Connective tissue
accumulated between the muscle fibers, and there were
gaps between myocardial cells. Pathological changes in
the ALA+RAP group (Figure 1c) were milder than those
in the RAP group. Most of the nuclei appeared normal,
the myocardial fibers did not show ruptures, and their
arrangement was slightly ordered.
3.2.2. Effect of ALA on ultrastructural changes in each
group
As shown in Figure 2, the tissue sections from the SHAM
group (Figure 2a) showed a normal ultrastructure,
while it was severely injured in the RAP group (Figure
2b), characterized by myofilament dissolution and
mitochondrial swelling and deformation. While the
myofilament dissolution and mitochondrial swelling and
deformation were rarely observed in the ALA+RAP group
(Figure 2c) compared with the RAP group (Figure 2b).
3.3. Effect of ALA on oxidative stress in each group
As shown in Table 4, compared with the SHAM group, the
contents of MDA and ROS were significantly increased
in the RAP group (p < 0.05), while SOD activity was
decreased (p < 0.05). Compared with the RAP group, the
contents of MDA and ROS were reduced in the ALA+RAP
group (p < 0.05), while SOD activity was enhanced (p <
0.05).

3.4. Effects of ALA on NOX2 and NOX4 in each group
3.4.1. Western blot
Compared with the SHAM group, expression of NOX2
and NOX4 in the atrial muscle tissue in the RAP group
was upregulated (p < 0.05). Thus, RAP induced the
upregulation of NOX2 and NOX4. Compared with the
RAP group, expression of NOX2 and NOX4 in the atrial
tissue in the ALA+RAP group was decreased (p < 0.05)
compared with the SHAM group (Tables 5and 6, Figure
3 and 4).
3.4.2. Immunolocalization of NOX2
As shown in Figure 5, the yellow staining indicates positive
NOX2 expression. Compared with the SHAM group
(Figure 5a), the RAP group (Figure 5b) had a markedly
enlarged stained area, along with notably deepened yellow
staining. Compared with the RAP group (Figure 5b), the
staining area in the ALA+RAP group (Figure 5c) was
distinctly reduced, and the yellow staining was notably
lightened.
3.5. ELISA
Compared with the SHAM group, the NADPH oxidase
(NOX4) expression level in the RAP group was notably
upregulated (p < 0.05), and compared with the RAP
group, the expression of NADPH oxidase (NOX4) in the
ALA+RAP group was significantly downregulated (p <
0.05). Compared with the SHAM group, the expression
of NADPH oxidase (NOX4) in the ALA+RAP group was
slightly upregulated (p < 0.05) (Table 7, Figure 6).

Figure 1. Light photomicrographs of the rabbit’s heart stained with hematoxylin and
eosin (×200); (A) Myocardial fibers and nuclei in the SHAM group; (B) Myocardial
fibers and nuclei in the RAP group; (C) Myocardial fibers and nuclei in the ALA+RAP
group.
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Figure 2. Ultrastructural changes of the heart with transmission electron microscopy; (A)
The ultrastructure in the SHAM group; (B) The ultrastructural changes in the RAP group; (C)
The ultrastructural changes in the ALA+RAP group.

Table 4. Effects of ALA on MDA, SOD and ROS (n=10, x̄ ±s).
Group

MDA (nmol/mgprot)
(mmol/mgprot)

SOD (U/ mgprot)

ROS (μmol/mg)

SHAM

1.30 ± 0.33

432.19 ± 2.65

0.004 ± 0.001

RAP

4.52 ± 0.28

ALA+RAP

2.44 ± 0.23ab

a

a

107.50 ± 3.45

0.016 ± 0.002 a

302.09 ± 6.14ab

0.009 ± 0.001ab

a, p< 0.05 compared with the SHAM group; b, p< 0.05 compared with the RAP group.

Table 5. Effect of ALA on NOX2.
Group

NOX2/β-actin

SHAM

0.47 ± 0.09

RAP

1.12 ± 0.09a

ALA+RAP

0.68 ± 0.10ab

a, p< 0.05 compared with the SHAM group; b, p< 0.05 compared
with the RAP group.
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Table 6. Effect of ALA on NOX4.
Group

NOX4/β-actin

SHAM

0.60 ± 0.12

RAP

1.14 ± 0.11a

ALA+RAP

0.82 ± 0.07ab

a, p < 0.05 compared with the SHAM group; b, p < 0.05 compared with the
RAP group.

Figure 3. a, p< 0.05 compared with the SHAM group; b, p< 0.05
compared with the RAP group.

Figure 4. a, p < 0.05 compared with the SHAM group; b, p < 0.05
compared with the RAP group.
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Figure 5. Immunolocalization of NOX2 in myocardial tissue (×400); (A) Immunolocalization
of NOX2 in the SHAM group; (B) Immunolocalization of NOX2 in the RAP group; (C)
Immunolocalization of NOX2 in the ALA+RAP group.
Table 7. Effect of ALA on NADPH oxidase (NOX4).
Group

NADPH oxidase (pg/mL, n=10)

SHAM

1872.46 ± 161.73

RAP

3549.90 ± 413.94a

ALA+RAP

2348.67 ± 289.32ab

a, p < 0.05 compared with the SHAM group; b, p < 0.05 compared with
the RAP group.

Figure 6. a, p < 0.05 compared with the SHAM group; b, p < 0.05
compared with the RAP group.
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4. Discussion
In this study, the frequency adaptability of AERP
and AERP were measured to evaluate atrial electrical
remodeling [34]. After RAP stimulation, electrical
remodeling-related indicators in the RAP group developed
remarkable changes in the early stage, which manifests as a
shortened AERP and a loss of frequency adaptability. The
results of HE staining and the SEM showed that compared
with the SHAM group, rabbit atrial ultrastructure and
pathological structures were notably changed in the RAP
group. This further verifies that electrical remodeling and
structural remodeling are closely related to the genesis and
development of AF.
Oxidative stress participates in atrial electrical
remodeling and structural remodeling, thus giving rise
to lesions like atrial fibrosis [35,36]. This experiment
constructed an RAP rabbit model, and atrial muscle
oxidative stress-related indicators, namely, ROS, SOD
and MDA, were detected to reflect oxidative stress in the
atrial muscle tissue at the time of AF. Among them, ROS
is one of the major causes of oxidative stress, which plays
a vital role in the genesis and maintenance of AF [37]. As
was found in this experiment, among the oxidative stressrelated indicators, the ROS and MDA content increased
while SOD activity decreased in the RAP group compared
with the control group. Thus, RAP can reduce SOD activity,
destroying the first-line defense of ROS and interfering
with the balance between oxidation and antioxidation
regulation, which then increases ROS and MDA content.
These findings indicated that RAP could induce oxidative
stress injury, which has further verified that oxidative
stress is closely related to AF.
In addition, many studies have reported that
antioxidants can effectively improve atrial electrical
remodeling and structural remodeling [38,39]. However,
their clinical effects remain unsatisfying. Therefore, we
are looking forward to searching for a better upstream
therapeutic agent or treatment for AF. NADPH oxidase
is a major source of ROS in the body, the enhanced
activity of which is closely associated with the genesis and
development of AF [40–42]. In this experiment, compared
with the SHAM group, the expression levels of nox2 and
nox4 in the atrial muscle of the RAP group were distinctly
upregulated. This suggests that RAP can enhance NADPH
oxidase activity, thus promoting ROS production.
Consequently, NADPH oxidase targeted therapy may be a
novel effective treatment for preventing AF.
ALA is a naturally existing thiol antioxidant that
can eliminate most of the active substances produced
in the body as compared with general antioxidants.
Meanwhile, it can inhibit NADPH oxidase. Research on
the role of ALA in CVD has increased gradually due to
its unique features. It was discovered that ALA exerts
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antioxidative effects in CVDs through multiple pathways,
thus alleviating the genesis and progression of disease
[43–45]. However, research on its role in arrhythmia,
especially AF, is rarely reported. In this study, we observed
oxidative stress-related indicators and discovered that
the ALA+RAP group notably reduced the levels of
oxidative stress induced by RAP. Through HE staining
and the SEM results, compared with the RAP group, the
pathological structures in the ALA+RAP group were
significantly improved. Comparisons of the AERP and
AERP frequency adaptability among all groups showed
that ALA could delay RAP-induced changes in AERP and
AERP frequency adaptability. Furthermore, the results of
immunohistochemistry, Western blot and ELISA showed
that compared with the RAP group, the ALA+RAP group
had reduced expression of the NOX2 and NOX4 proteins.
Consequently, we speculate that ALA can improve atrial
electrical remodeling and structural remodeling in an
RAP model, thus effectively preventing the genesis and
progression of AF. Apart from antioxidative effects such
as the direct inactivation of ROS, its mechanism of action
may be to partially inhibit NADPH oxidase activity and
reduce ROS production, thus improving atrial remodeling
in this RAP model. It was verified in this experiment that
ALA can directly inactivate ROS in an RAP rabbit model.
In addition, it can partly inhibit NADPH oxidase activity
and reduce ROS production, thus delaying the progression
of AF. These results have provided a certain theoretical
foundation for the antioxidant treatment of AF.
There are some limitation in this study. First of all,
because this is an invasive and open atrial rapid pacing
model, it may be difficult to maintain a longer period of
time during rapid atrial pacing, but this invasive pacing
mode also ensures that the atrium can be paced more
effectively. Second, our research content can continue to
expand, such as inflammatory response, so as to clarify
the specific mechanism of ALA and NADPH in atrial
fibrillation, which will continue to be carried out in our
future research. Finally, if this study has a larger sample
size and more experimental groups, then it may have more
promotion and application value.
In conclusion; this article demonstrates the electrical
and structural remodeling of the atrium in a rapid atrial
pacing model. This study used lipoic acid for the first
time in atrial rapid pacing models and proved that ALA
intervention could inhibit atrial electrical remodeling and
structural remodeling. Its mechanism may be to reduce
oxidative stress injury by inhibiting the activity of NADPH
oxidase.
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